Angiotensin II receptor antagonists
Background
- Also known as angiotensin receptor blockers (ARBs), AT1-receptor antagonists or sartans
- A group of pharmaceuticals that modulate the renin–angiotensin system, they block activation of angiotensin II AT1 receptors, thus preventing angiotensin II from binding
- Main uses are in the treatment of hypertension, diabetic nephropathy and congestive heart failure
Medications
| Drug | Trade Name | Biological half-life [h] | Protein binding [%] | Bioavailability [%] | Renal/hepatic clearance [%] | Food effect | Daily dosage [mg] |
|---|---|---|---|---|---|---|---|
| Losartan | Cozaar | 6-9 h | 98.7% | 33% | 10%/90% | Minimal | 50–100 mg |
| EXP 3174 | 6–9 h | 99.8% | – | 50%/50% | – | – | |
| Candesartan | Atacand | 9h | >99% | 15% | 60%/40% | No | 4–32 mg |
| Valsartan | Diovan | 6 h | 95% | 25% | 30%/70% | No | 80–320 mg |
| Irbesartan | Avapro | 11–15 h | 90–95% | 70% | 1%/99% | No | 150–300 mg |
| Telmisartan | Micardis | 24 h | >99% | 42–58% | 1%/99% | No | 40–80 mg |
| Eprosartan | Teveten | 5 h | 98% | 13% | 30%/70% | No | 400–800 mg |
| Olmesartan | Benicar/Olmetec | 14–16 h | >99% | 29% | 40%/60% | No | 10–40 mg |
| Azilsartan | Edarbi | 11 h | >99% | 60% | 55%/42% | No | 40–80 mg |
| Fimasartan | Kanarb | 7-11 h | >97% | 30-40% | - | - | 30–120 mg |